BP control in diabetic patients is often poor. The contribution of secondary hypertension due to undiagnosed PA in hypertensive type 2 diabetic patients is not well studied. We prospectively screened 100 consecutive Asian type 2 diabetic patients with difficult-to-control or resistant hypertension for PA. PAC (pmol/L) to PRA (ng/mL/h) ratio was measured; those with PAC-to-PRA ratio >550 (corresponding PAC >415) underwent intravenous 0.9% SLT. Patients with PAC ≥140 following SLT had CT adrenals and bilateral AVS. Thirteen patients (13%) were confirmed to have PA, and all had resistant hypertension. Eight had a surgically correctable form of PA. Patients with PA had higher mean (SD) systolic [159.0 (10.6) vs. 146.0 (10.7) mmHg, p=0.001] and diastolic BP [94.6 (6.0) vs. 87.6 (5.9) mmHg, p=0.001], lower serum potassium [3.5 (0.6) vs. 4.3 (0.5) mmol/L, p=0.001], and higher PAC [679.3 (291.0) vs. 239.5 (169.4) pmol/L, p=0.001]. Identification and institution of definitive treatment for PA resulted in better BP control and in a reduction in the use of antihypertensive medications. Our findings demonstrate a high prevalence of PA in type 2 diabetic patients with resistant hypertension. Systematic screening for PA in this select group is recommended, as targeted treatment improves BP control.
Pyorala, K., Laakso, M., Uusitupa, M. ( 1987) Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev3: 463-524.
2.
McFarlane, S.I. , Sowers, J.R. (2003) Cardiovascular endocrinology 1: aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease. J Clin Endocrinol Metab88: 516-23.
3.
Arauz-Pacheco, C., Parrott, M.A., Raskin, P. (2003) Treatment of hypertension in adults with diabetes. Diabetes Care26 (suppl 1): S80-2.
4.
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. (1998) BMJ317: 703-13.
5.
Hansson, L. ( 2002) Hypertension management in 2002: where have we been? where might we be going?Am J Hypertens15: 101S-107S.
6.
Saydah, S.H. , Fradkin, J., Cowie, C.C. (2004) Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes . JAMA291: 335-42.
7.
Randeree, H.A. , Omar, M.A., Motala, A.A., Seedat, M.A. (1992) Effect of insulin therapy on blood pressure in NIDDM patients with secondary failure. Diabetes Care15: 1258-63.
8.
Nosadini, R. , Sambataro, M., Thomaseth, K., et al. (1993) Role of hyperglycemia and insulin resistance in determining sodium retention in non-insulin-dependent diabetes. Kidney Int44: 139-46.
9.
Young, W.F. Jr. (2002) Primary aldosteronism: management issues . Ann N Y Acad Sci970: 61-76.
10.
Rocha, R., Funder, J.W. ( 2002) The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci970: 89-100.
11.
Schiffrin, E.L. (2006) Effects of aldosterone on the vasculature. Hypertension47: 312-18.
12.
Asbun, J., Villarreal, F.J. ( 2006) The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol47: 693-700.
13.
Neumann, S., Huse, K., Semrau, R., et al. (2002) Aldosterone and D-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro. Hypertension39: 756-60.
14.
Cooper, S.A., Whaley-Connell, A., Habibi, J., et al. (2007) Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol293: H2009-23.
15.
Sowers, J.R., Epstein, M., Frohlich, E.D. ( 2001) Diabetes, hypertension, and cardiovascular disease: an update. Hypertension37: 1053-9.
16.
Milliez, P. , Girerd, X., Plouin, P.F., et al. (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism . J Am Coll Cardiol45: 1243-8.
17.
Selvaraj, J. , Muthusamy, T., Srinivasan, C., Balasubramanian , K.(2009) Impact of excess aldosterone on glucose homeostasis in adult male rat. Clin Chim Acta407: 51-7.
18.
Sowers, J.R. , Whaley-Connell, A., Epstein, M.(2009) Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med150: 776-83.
19.
Corry, D.B. , Tuck, M.L. (2003) The effect of aldosterone on glucose metabolism. Curr Hypertens Rep5: 106-9.
20.
Giacchetti, G., Sechi, L.A., Rilli, S., Carey, R.M. (2005) The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab16: 120-6.
21.
Rocchini, A.P. , Moorehead, C., DeRemer, S., Goodfriend, T.L., Ball, D.L. (1990) Hyperinsulinemia and the aldosterone and pressor responses to angiotensin II. Hypertension15: 861-6.
22.
Petrasek, D. , Jensen, G., Tuck, M., Stern, N. (1992) In vitro effects of insulin on aldosterone production in rat zona glomerulosa cells. Life Sci50: 1781-7.
23.
Umpierrez, G.E., Cantey, P., Smiley, D., et al. (2007) Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care30: 1699-703.
24.
Moser, M., Setaro, J.F. ( 2006) Clinical practice. Resistant or difficult-to-control hypertension . N Engl J Med355: 385-92.
25.
Mulatero, P. , Stowasser, M., Loh, K.C., et al. (2004) Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab89: 1045-50.
26.
Janka, H.U. , Dirschedl, P. (1985) Systolic blood pressure as a predictor for cardiovascular disease in diabetes. A 5-year longitudinal study. Hypertension7: 1190-4.
27.
Stamler, J. , Vaccaro, O., Neaton, J.D., Wentworth, D. (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16: 434-44.
28.
Adler, A.I. , Stratton, I.M., Neil, H.A., et al. (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ321: 412-19.
29.
Hansson, L. , Zanchetti, A., Carruthers, S.G., et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet351: 1755-62.
30.
Wang, T.J., Vasan, R.S. ( 2005) Epidemiology of uncontrolled hypertension in the United States. Circulation112: 1651-62.
31.
Young, W.F. (2007) Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf)66: 607-18.
32.
Mosso, L., Carvajal, C., Gonzalez, A., et al. (2003) Primary aldosteronism and hypertensive disease . Hypertension42: 161-5.
33.
Fardella, C.E. , Mosso, L., Gomez-Sanchez, C., et al. (2000) Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab85: 1863-7.
34.
Gordon, R.D. , Stowasser, M., Tunny, T.J., Klemm, S.A., Rutherford, J.C. (1994) High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol21: 315-18.
35.
Hiramatsu, K., Yamada, T., Yukimura, Y., et al. (1981) A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med141: 1589-93.
36.
Lim, P.O. , Rodgers, P., Cardale, K., Watson, A.D., MacDonald, T.M. (1999) Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet353: 40.
37.
Loh, K.C. , Koay, E.S., Khaw, M.C., Emmanuel, S.C., Young, W.F. Jr. (2000) Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab85: 2854-9.
38.
Westerdahl, C., Bergenfelz, A., Isaksson, A., Wihl, A., Nerbrand, C., Valdemarsson, S. (2006) High frequency of primary hyperaldosteronism among hypertensive patients from a primary care area in Sweden. Scand J Prim Health Care24: 154-9.
39.
Williams, J.S. , Williams, G.H., Raji, A., et al. (2006) Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia . J Hum Hypertens20: 129-36.
40.
Fallo, F., Veglio, F., Bertello, C., et al. (2006) Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab91: 454-9.
41.
Catena, C., Lapenna, R., Baroselli, S., et al. (2006) Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab91: 3457-63.
42.
Calhoun, D.A. , Nishizaka, M.K., Zaman, M.A., Thakkar, R.B., Weissmann, P. (2002) Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension40: 892-6.
43.
Schwartz, G.L. , Turner, S.T. (2005) Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem51: 386-94.
44.
Rossi, G.P. , Bernini, G., Caliumi, C., et al. (2006) A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients . J Am Coll Cardiol48: 2293-300.
45.
Douma, S., Petidis, K., Doumas, M., et al. (2008) Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet371: 1921-6.
